Mallinckrodt Pharmaceuticals and Endo Inc., both companies with significant histories in the pharmaceutical industry, are reportedly engaged in negotiations for a merger that could be valued at approximately $7 billion. This merger discussion follows both companies’ emergence from bankruptcy after facing legal and financial challenges related to their involvement in the US opioid crisis. The proposed merger could be announced imminently, according to individuals familiar with the negotiations.
The talks suggest that the resulting entity post-merger would see each company’s investors owning about 50% of the shares, potentially creating a new heavyweight in the sector. This combined entity is anticipated to be publicly traded on the New York Stock Exchange. Recent reports indicate that this development could be confirmed as early as this week.
Mallinckrodt has been a long-standing name in the pharmaceutical industry, heavily involved in the production of generic and specialty drugs. Similarly, Endo has made headlines with its diverse portfolio of products, including those aimed at treating various pain-related and chronic conditions. Both companies have previously declared bankruptcy as they navigated the complex legal responsibilities stemming from their roles in the opioid epidemic.
This potential merger highlights the evolving landscape of the pharmaceutical industry as companies reassess and readjust their strategies in a challenging legal and regulatory environment. For more information, you can access the original Bloomberg article.